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Myoﬁbromas are rare ﬁbrous tumors, which can be solitary (myoﬁbroma) or multiple (myoﬁbromatosis).
They can be dermatological or visceral in origin. Usually the dermatological tumors are benign and have
good prognosis while those with visceral involvement are associated with poor outcome. The extent and
location of these lesions are the important prognostic factors with a mortality rate of 75% with multifocal
visceral involvement. The major difﬁculty in diagnosis is variable clinical presentation of these tumors.
We report two cases which represent the wide clinical spectrum of these tumors ranging from protein
losing enteropathy in infancy to liver tumor in childhood. Delay in the diagnosis and inappropriate
management can be life threatening as each requires a speciﬁc treatment approach.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Myoﬁbromas are rare ﬁbrous tumors, which can be solitary
(myoﬁbroma) or multiple (myoﬁbromatosis). They can be either
dermatological or visceral in origin. The dermatological myoﬁ-
bromas commonly involve the head, neck and trunk whereas the
visceral forms involve the abdomen, pelvis, lungs and retro peri-
toneum [1]. Usually the dermatological tumors are benign and have
good prognosis with high spontaneous resolution rates [2] while
those with visceral involvement are associated with poor outcome.
The extent and location of these lesions are the important prog-
nostic factors with a mortality rate of 75% with multifocal visceral
involvement [3].
1. Case report
We report two cases of myoﬁbromas presenting with a varied
spectrum of symptoms.
1.1. Case 1
Our ﬁrst case is a newborn, delivered vaginally at 36 weeks of
gestation with a mass in his chest reported on a prenatalBY-NC-SA license (http://
nancial support or any other
1 9143670001.
ri@yahoo.com (D. Tewari).
Published by Elsevier Inc. All rightultrasound. Postnatal chest X-ray showed a soft tissue mass on left
lateral thoracic wall with displacement of ribs. Histology of the
mass revealed a benign infantile myoﬁbroma of the chest wall. At
the age of 11/2 months he was hospitalized with 2 weeks history of
watery diarrhea, hypoalbuminemia (albumin: 1.6 g/dl) and
thrombocytopenia (platelets: 109 k/cu mm). His immunizations
were up to date and the family history was unremarkable. He was
given albumin transfusions and discharged on hydrolyzed milk
protein formula for the presumptive diagnosis of cow’s milk protein
allergy. Despite receiving a hydrolyzedmilk protein formula, hewas
hospitalized again at 3 months of age for persistent diarrhea and
failure to gain weight. The physical exam was remarkable for the
weight at 5th centile and length at 10th centile on the growth chart
with periorbital edema. Laboratory evaluation revealed anemia
(Hgb: 9.8 g/dl), elevated inﬂammatory markers (platelets: 559 k/
cu mm, ESR: 42 mm/h, CRP: 16 mg/dl), hypoproteinemia and
hypoalbuminemia (total protein 3.5 g/dl, albumin1.1 g/dl). Normal
lab results included serum electrolytes, hepatic proﬁle, thyroid
function tests, T and B cell counts, immune electrophoresis and
stool studies (microscopy, acid fast stain and cultures). Since he was
hypoalbuminemic again he received multiple albumin infusions.
Interestingly, within 2e3 days of each infusion his serum albumin
levels would drop to 1.1 g/dl. During the hospitalization he was
placed on continuous G tube feeds of 120 kcal/kg/day of hydrolyzed
milk protein formula, which resulted in a weight gain of 30 gm/day.
A repeat chest X-ray was similar to the previous X-ray with no
change in the size of the myoﬁbroma. Abdominal ultrasound and
UGI series were normal. On endoscopy he had denuded duodenal
mucosa. Colonoscopy was remarkable for multiple polypoid tumorss reserved.
Fig. 1. Multiple polypoid tumors masses seen on colonoscopy (case 1).
Fig. 3. Sagittal image of the liver mass with central calciﬁcation extending from the left
lobe of the liver primarily T2 hyperintense, without evidence of deﬁned cystic com-
ponents (case 2).
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partial villous atrophy, increased mononuclear cells and extensive
myoﬁbroblastic proliferation in the lamina propria. Colon biopsy
was remarkable for destruction of crypts and marked myoﬁbro-
blastic proliferation in the lamina propria. The trichrome staining
conﬁrmed increased collagen deposition in lamina propria. He was
diagnosed with visceral infantile myoﬁbrosis (IM). He was started
on methotrexate and vinblastine. Following the ﬁrst cycle of
chemotherapy his diarrhea improved and he gained weight. In
addition his serum albumin levels stabilized suggesting resolving
protein losing enteropathy. On his follow up visit 8 months after the
chemotherapy he was maintaining his growth curve with complete
resolution of diarrhea, hypoproteinemia and hypoalbuminemia.Fig. 2. Cornonal image of the large heterogenous liver mass with central calciﬁcation
extending from the left lobe of the liver, measures up to 21.7 cm in height, 17.3 cm in
width, and 12.5 cm in depth (case 2).1.2. Case 2
The patient is an 11-year-old girl, who presented with 1 day
history of severe abdominal pain. She also reported increasing
abdominal size, weight loss, fatigue and early satiety for 4 months.
Her past medical history and family history were unremarkable
and immunizations were up-to-date. On physical exam she was on
25th centile for weight and 50th centile for height, pale and
tachycardic (122). Her abdomen was distended with a ﬁrm, non-
tender, right upper quadrant mass extending from the right costal
margin down to the umbilicus, crossing the midline, measuring
18 cm in length and 16 cm in maximum width. There was no
splenomegaly, no visible abdominal veins and no edema. Her labs
showed WBC count of 9.2 k/cu mm, hemoglobin 7.8 g/dl, Hct 26.1
and platelets of 574 k/cu mm. Her liver function tests and coagu-
lation studies were normal except for the albumin of 3 g/dl. Viral
studies for hepatitis A, B, C, EBV, CMV and adenovirus were
negative. AFP was normal. CT scan revealed a large liver mass,
predominantly involving the left hepatic lobe measuring
21.7  17.3  12.5 cm with portal vein thrombus and central
calciﬁcation (Figs. 2 and 3). MRI conﬁrmed the CT scan ﬁndings
with no evidence of metastasis. Histological diagnosis following
wedge biopsy was inﬂammatory myoﬁbroblastic tumor of the
liver. The tumor cells were positive for vimentin, smooth muscle
actin and CD31 on immunohistochemical staining. The trial of
chemotherapy failed to show improvement. She had a successful
liver transplant with tumor resection. She is doing well 6 months
post transplant with no recurrences.
2. Discussion
IM was ﬁrst described in 1951 by Williams and Schrum as a
congenital ﬁbrosarcoma [4]. Subsequently various other descriptive
terms were used like congenital multiple ﬁbromatosis [5], multiple
mesenchymal hamartomatosis [6], diffuse congenital ﬁbromatosis
[7] and multiple vascular leiomyomas of the newborn [8]. The term
‘Infantile Myoﬁbromatosis’ was coined by Chung and Enzinger in
their case series of 61 patients [9].
Fig. 5. Spindle shaped cells with elongated nuclei and abundant eosinophilic cyto-
plasm seen microscopically.
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[10]. The majority of cases present at birth or shortly thereafter [3],
occurring more commonly in boys than girls [1]. The tumors can be
solitary or multicentric. The solitary forms are common in males
(69%) and predominantly affect the soft tissues of the head-neck
and the trunk while the multicentric forms are common in females
(63%) and predominate in bones and viscera [11,12].
Myoﬁbroma (case 2) is a solitary benign tumor of myoﬁbroblasts
whereasmyoﬁbromatosis (case 1) describesmultiple, simultaneous
myoﬁbromas at different sites in various organs.
The multifocal intestinal involvement (case 1) is very uncom-
mon and the description is based on few case reports [13,14]. These
intestinal myoﬁbromas are reported in jejunum and ileum [15,16],
rarely involving duodenum [8] and colon [17] as seen in case 1. GI
tract involvement presents as diarrhea, intestinal obstruction,
perforation or intussusception [18].
IM of the liver (case 2) is rare andwas ﬁrst described by Pack and
Baker in 1953 [19]. Hepatic IMTs occur predominantly in right lobe.
The pathogenesis has been described as benign reactive process
progressing to inﬂammatory or a malignant neoplasm [20]. In
various case reports these tumors have also been associated with
infections as Klebsiella, C. difﬁcile, Corynebacterium, Eikenella
corrodens, actinomycosis, hepatitis C, B and EpsteineBarr viruses
[21e25], Immunosuppression [26], radiotherapy [27], autoimmune
disorders and malignancies [28].
Grossly these tumors can range from 1 to 27 cm in size. Micro-
scopically they are composed of spindle shaped cells in whorls and
fascicles [29]. The cellular origin has been postulated to be from the
‘myoﬁbroblast’ a mesenchymal cell with features of both ﬁbroblast
and smooth muscle. The histological signiﬁcance of myoﬁbroblasts
was described in 1971 by Gabbiani et al. [30,31] which stains pos-
itive for actin, vimentin and muscle speciﬁc antigen on immune
histochemical staining as seen in our case. On cytogenetic analysis
nearly half of the patients with IM show evidence of genetic
translocation on chromosome 2p23 with ALK (anaplastic lym-
phoma kinase) protein over expression in the tumor myoﬁbroblasts
[32e35] (Figs. 4 and 5).
The associated laboratory ﬁndings are anemia, leukocytosis,
thrombocytosis, high ESR and CRP [20].Fig. 4. Myoﬁbroblastic tumor showing spindle shaped cells with elongated nuclei and
abundant eosinophilic cytoplasm on pathology.The usual management approach is to conﬁrm the diagnosis by
biopsy of one of the lesions and then search for evidence of visceral
involvement. Therefore the work up includes chest and abdominal
imaging with X-rays, sonogram, echocardiography, whole body
MRI/CT scan and skeletal survey [36].
There are several case reports about solitary tumors that pre-
sented with intestinal obstruction that did well with resection of
the tumor [15,16]. The recurrence rate after excision is 7e10% [37].
Subsequent periodic clinical and radiological evaluation is war-
ranted until the condition is stable. Given the high mortality with
diffuse visceral involvement, there have been attempts to treat
such cases with chemotherapy. Success utilizing combination
chemotherapy i.e.: vincristine, actinomycin B & cyclophosphamide
has been reported [38,39]. However the real value of such therapy
is difﬁcult to ascertain as there is a tendency to spontaneously
involute [40]. Maternal estrogen has also been postulated to be
responsible for tumor growth in utero but anti estrogen therapy
has not been found to be effective [41]. For localized destructive
disease, radiotherapy and local steroid injections have been tried
as well [42].
3. Conclusion
The major difﬁculty in diagnosis of IMs is variable clinical pre-
sentation and potential multi organ involvement. We report two
cases which represent the wide clinical spectrum of the IM ranging
fromprotein losing enteropathy in infancy to liver tumor. Each has a
different treatment approach. Delay in the diagnosis and inappro-
priate management can be life threatening.
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